Top

Published in:

01-12-2009 | Original Article

A genetic variant of immunoglobulin γ2 is strongly associated with immunity to mucin 1 in patients with breast cancer

Authors: Janardan P. Pandey, Paul J. Nietert, Kersti Klaamas, Oleg Kurtenkov

Published in: Cancer Immunology, Immunotherapy | Issue 12/2009

Abstract

High levels of antibodies to mucin 1 (MUC1), a membrane-bound glycoprotein that is overexpressed in adenocarcinomas, are associated with good prognosis in patients with breast cancer. The aim of the present investigation was to determine whether GM and KM allotypes—genetic markers of IgG heavy chains and κ-type light chains, respectively—contribute to the magnitude of natural antibody responsiveness to MUC1 in patients with breast cancer. A total of 153 Caucasian subjects with breast cancer were allotyped for several GM and KM markers. These subjects were also characterized for IgG and IgM antibodies to MUC1. Anti-MUC1 IgG antibody levels in subjects who were carriers of the immunoglobulin γ2 allele GM 23 were significantly higher than in those who were noncarriers (P = 0.003). These results could potentially divide the population into high or low responders to MUC1, which has important implications for MUC1-based immunotherapeutic interventions in breast cancer.

Pandey JP (2001) Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 19:613–617CrossRef

Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA (2007) HLA supertypes and immune responses to measles–mumps–rubella viral vaccine: findings and implications for vaccine design. Vaccine 25:3090–3100PubMedCrossRef

Dhiman N, Ovsyannikova IG, Cunningham JM, Vierkant RA, Kennedy RB, Pankratz VS, Poland GA, Jacobson RM (2007) Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes. J Infect Dis 195:21–29PubMedCrossRef

Forthal DN, Gilbert PB, Landucci G, Phan T (2007) Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 178:6596–6603PubMed

Lieberman R, Stiffel C, Asofsky R, Mouton D, Biozzi G, Benacerraf B (1972) Genetic factors controlling anti-sheep erythrocyte antibody response and immunoglobulin synthesis in backcross and F2 progeny of mice genetically selected for “high” or “low” antibody synthesis. J Exp Med 136:790–798PubMedCrossRef

Pandey JP, Shannon BT, Tsang KY, Fudenberg HH, Camblin JG (1982) Heterozygosity at Gm loci associated with humoral immunity to osteosarcoma. J Exp Med 155:1228–1232PubMedCrossRef

Sarvas H, Rautonen N, Käyhty H, Kallio M, Mäkelä O (1990) Effect of Gm allotypes on IgG2 antibody responses and IgG2 concentrations in children and adults. Int Immunol 2:317–322PubMedCrossRef

Pandey JP, Page GP, Silver RM, LeRoy EC, Bona CA (2001) Anti-fibrillin-1 autoantibodies in systemic sclerosis are Gm and Km allotype restricted. Exp Clin Immunogenet 18:123–129PubMedCrossRef

Pandey JP, Nietert PJ, Mensdorff-Pouilly S, Klaamas K, Kurtenkov O (2008) Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer. Cancer Res 68:4442–4446PubMedCrossRef

10.

Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249–293PubMedCrossRef

11.

von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574–583

12.

von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, van Kamp GJ, Kok A, van Uffelen K, Snijdewint FG, Paul MA, Meijer S, Hilgers J (1998) An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumour Biol 19:186–195CrossRef

13.

Schanfield MS, van Loghem E (1986) Human immunoglobulin allotypes. In: Weir DM (ed) Handbook of experimental immunology. Blackwell, Boston, pp 94.1–94.18

14.

Granoff DM, Suarez BK, Pandey JP, Shackelford PG (1988) Genes associated with the G2 m(23) immunoglobulin allotype regulate the IgG subclass responses to Haemophilus influenzae type b polysaccharide vaccine. J Infect Dis 157:1142–1149PubMed

15.

Granoff DM, Holmes SJ (1992) G2 m(23) immunoglobulin allotype and immunity to Haemophilus influenzae type b. J Infect Dis 165:S66–S69PubMed

16.

Ambrosino DM, Schiffman G, Gotschlich EC, Schur PH, Rosenberg GA, DeLange GG, van Loghem E, Siber GR (1985) Correlation between G2 m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. J Clin Invest 75:1935–1942PubMedCrossRef

17.

Pandey JP, French MAH (1996) Gm phenotypes influence the concentrations of the four subclasses of immunoglobulin G in normal human serum. Hum Immunol 51:99–102PubMedCrossRef

18.

Morell A, Skvaril F, Steinberg AG, Van Loghem E, Terry WD (1972) Correlations between the concentrations of the four sub-classes of IgG and Gm Allotypes in normal human sera. J Immunol 108:195–206PubMed

19.

von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J (2000) Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 86:702–712CrossRef

20.

Martin SW, Goodnow CC (2002) Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. Nat Immunol 3:182–188PubMedCrossRef

21.

Wakabayashi C, Adachi T, Wienands J, Tsubata T (2002) A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science 298:2392–2395PubMedCrossRef

22.

Morahan G, Berek C, Miller JFAP (1983) An idiotypic determinant formed by both immunoglobulin constant and variable regions. Nature 301:720–722PubMedCrossRef

23.

Moxley G, Gibbs RS (1992) Polymerase chain reaction-based genotyping for allotypic markers of immunoglobulin kappa shows allelic association of Km with kappa variable segment. Genomics 13:104–108PubMedCrossRef

24.

Pritsch O, Hudry-Clergeon G, Buckle M, Petillot Y, Bouvet JP, Gagnon J, Dighiero G (1996) Can immunoglobulin C_H1 constant region domain modulate antigen binding affinity of antibodies? J Clin Invest 98:2235–2243PubMedCrossRef

25.

Torres M, Fernández-Fuentes N, Fiser A, Casadevall A (2007) The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem 282:13917–13927PubMedCrossRef

26.

Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47PubMedCrossRef

27.

Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S (2007) High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 257:47–55PubMedCrossRef

28.

Pandey JP, Prohászka Z, Veres A, Füst G, Hurme M (2004) Epistatic effects of genes encoding immunoglobulin GM allotypes and interleukin-6 on the production of autoantibodies to 60- and 65-kDa heat-shock proteins. Genes Immun 5:68–71PubMedCrossRef

29.

Lenoir AA, Pandey JP, Granoff DM (1988) Antibody responses of black children to Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in relation to the Km(1) allotype. J Infect Dis 157:1242–1245PubMed

30.

Grubb R (1995) Advances in human immunoglobulin allotypes. Exp Clin Immunogenet 12:191–197PubMed

Title: A genetic variant of immunoglobulin γ2 is strongly associated with immunity to mucin 1 in patients with breast cancer
Authors: Janardan P. Pandey
Paul J. Nietert
Kersti Klaamas
Oleg Kurtenkov
Publication date: 01-12-2009
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 12/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0709-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2009

Impact of aging on cancer immunity and immunotherapy

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b+/CCR3−/Gr-1− cells cytotoxic against the tumor cells

The effect of aging on OX40 agonist-mediated cancer immunotherapy

Cancer, aging and immunotherapy: lessons learned from animal models

Immunosenescence and cancer vaccines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer